Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0344307 (analgesia)
 28,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A multi-centre, double-blind, crossover study was carried out in 80 patients with rheumatoid arthritis to compare the efficacy and side-effect profiles of two formulations of indomethacin. Patients were allocated at random to receive 75 mg indomethacin per day either as 1 controlled-release tablet at night or as 1 immediate-release capsule given 3-times a day for a period of 4 weeks before being crossed over to receive the alternative treatment for a further 4 weeks. Pain scores, daily symptomatology and the requirement for escape analgesia recorded by both investigator and patient indicated that controlled-release indomethacin tablets, 75 mg given at night, was as efficacous as immediate-release indomethacin capsules given 3-times daily. However, the controlled-release formulation had a superior side-effect profile with a reduced incidence of abdominal/epigastric pain compared to the immediate-release preparation.
 ...
PMID:A comparison of two formulations of indomethacin ('Flexin Continus' tablets and 'Indocid' capsules) in the treatment of rheumatoid arthritis. 220 49

Of one hundred patients originally entered for this trial eighty-three with acute musculo-skeletal disorders were treated with either naproxen sodium (SYNFLEX, Syntex), 550 mg initially followed by 275 mg four times daily, or piroxicam (FELDENE, Pfizer), 20 mg twice daily for two days then 20 mg once daily. Patients were assessed at admission, on day 4 and on day 8. Pain on passive movement, tenderness, swelling and limitation of function were evaluated and patients also completed a daily self-assessment form. Pain relief was recorded by the patient for 4 hours following the first dose. No statistically significant differences were detected between the treatment groups for any of the efficacy measurements. Of the eighty-three patients analysed, twenty-four patients withdrew from treatment twenty of whom did not need further analgesia (13 in the naproxen sodium group and 7 in the piroxicam group). Three patients experienced side-effects; all were in the piroxicam group, and one patient withdrew from the study because of epigastric pain. Both naproxen sodium and piroxicam proved effective in the treatment of musculo-skeletal disorders. Naproxen sodium did not give rise to any side-effects.
 ...
PMID:Naproxen sodium and piroxicam in acute musculo-skeletal disorders. 646 34

Fifty-eight coelio-splanchnic nerve blocks by alcoholisation were done for thirty-two patients at the regional Center of the Fight against Cancer at Montpellier for persistent neoplastic pain of the pancreatico-solar type. In 15 cases (46,6 p. cent), the pancreatico-solar syndrome is the initial sign of a primitive or secondary supra-mesocolic cancer. In 12 cases, the hyperalgic syndrome discloses the extension or recidive of the tumor. According to etiologies, the illnesses were as follows: --pancreatic neoplasias I or II: 13 cases, --hepato-biliary lesions I or II: 11 cases, --peritoneal carcinosis: 4 cases, --invasion of retro-peritoneal nodes: 4 cases. Epigastric pain irradiating to the left para-vertebral area are resistant to analgesias; 95 p. cent of these patients received morphinic drugs for several days, if not weeks. The splanchnic nerves were reached by a posterior high lumbar injection according to the Kappis and Labat technic. A block with 2 p. cent lidocaine is immediately followed by alcoholisation by 99,8 p. cent ethanol. According to patient status, the blocks to the left and right were done at once or at several visits. The block by lidocaine gives immediate analgesia thereby indicating the proper placement of the injection. The coeliac alcoholisation assures the neurolysis of the splanchnic nerves. The antalgic effect lasts a variable time, averaging 42 days (varying from 2 to 240 days). The antalgic action always allows the discontinuation of morphinic drugs and increases the efficacy of minor analgesics, if necessary. All the same, 18/25 received morphine during their last few days before death.
 ...
PMID:[Splanchnic nerve blocks by alcoholisation in pancreatico-solar hyperalgia of tumoral origin (author's transl)]. 730 43

Piroxicam-beta-cyclodextrin is a complex of the established nonsteroidal antiinflammatory drug (NSAID) piroxicam and an inert cyclic macromolecule, beta-cyclodextrin. In clinical trials in patients with rheumatic diseases or pain arising from other conditions, it was as effective an analgesic as standard piroxicam, and showed a faster onset of action on the first day of treatment. In short term pharmacodynamic studies in healthy volunteers, piroxicam-beta-cyclodextrin was equivalent to or tended to show less gastrointestinal mucosal toxicity than standard piroxicam, as assessed by endoscopy and faecal blood loss. However, no data are available on its comparative gastrointestinal mucosal effects from long term clinical trials using similar measures. Preliminary findings from a clinical study suggest piroxicam-beta-cyclodextrin caused fewer gastroduodenal lesions than tenoxicam. As with other NSAIDs, the majority of adverse events associated with piroxicam-beta-cyclodextrin in clinical trials were gastrointestinal in origin, with epigastric pain, heartburn and nausea the most common. Thus, piroxicam-beta-cyclodextrin is an effective agent in patients with rheumatic diseases or other pain states. When rapid analgesia is required in the initial treatment of acute pain, the faster onset of action of piroxicam-beta-cyclodextrin may be an advantage over the parent compound; however, this is unlikely to be important during long term therapy. The results of further long term trials are awaited before firm conclusions can be reached regarding the gastrointestinal tolerability of piroxicam-beta-cyclodextrin compared with that of standard piroxicam and other NSAIDs.
 ...
PMID:Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states. 753 98

The non-steroidal anti-inflammatory drug (NSAID) Ketoprofen (Profenid) is used as intravenous monotherapy incorporated in 0.9% normal saline solution (100 mg Ketoprofen ampoule + 200 ml normal saline) in the treatment of renal colic. We present our experience in 65 patients complaining of clinically diagnosed renal colic who were treated by intravenous saline-Ketoprofen. Prospective investigations revaled urinary calculi in 51 patients, oxaluria (crystalluria) in 5, acute colitis in 2, severe myositis in 2, negative investigations in 3 and radiculitis in 2 patients. Positive response was observed in 93.8% of patients as far as pain relief is concerned. Pain relief started within 5-7 minutes after beginning the infusion. Duration of analgesic effect ranged between 4 and 12 hours. Repeating the injection was done for maintenance of analgesia. Side effects included drowsiness in 2 patients, palpitation in 1 patient, epigastric pain in 1, muscular cramp in 1 patient. Ketoprofen, an antiprostaglandin, is a powerful anti-inflammatory and potent analgesic. Intravenous saline-Ketoprofen is a good emergency treatment for acute episodes of renal colic.
 ...
PMID:Emergency treatment of renal colic with intravenous ketoprofen. 759 85

The anticardiolipin or antiphospholipid antibody syndrome is characterized by an increased incidence of venous and arterial thromboses. This syndrome may occur in association with systemic lupus erythematosus or independently. Gastroenterological manifestations have included Budd-Chiari syndrome, hepatic infarction, esophageal necrosis with perforation, intestinal ischemia and infarction, pancreatitis, and colonic ulceration. We report a 39-yr-old man with antiphospholipid antibody syndrome complicated by adrenal insufficiency secondary to bilateral adrenal infarction who presented with severe epigastric pain. Endoscopic evaluation disclosed progressive gastric ulceration with necrosis in the distal body. Angiography revealed no vasculitis. Because of intractable pain despite intravenous anticoagulation and narcotic analgesia, the patient was taken to surgery, and an antrectomy with Billroth II gastrojejunostomy was performed. Histological examination revealed widespread vascular occlusive disease involving veins, small arteries, and arterioles present in all layers of the stomach and the perigastric fat consistent with the vasculopathy of the antiphospholipid antibody syndrome. Treatment with high intensity oral anticoagulation and corticosteroids resulted in clinical and endoscopic improvement. This case report extends the gastroenterological manifestations of the antiphospholipid antibody syndrome to include giant gastric ulceration and emphasizes the importance of anticoagulation in treatment.
 ...
PMID:Giant gastric ulceration associated with antiphospholipid antibody syndrome. 912 46

Since the introduction of H2 receptor antagonists and inhibitors of the acid pump, the indications for the surgical management of peptic disease have decreased significantly. However some patients presenting bleeding, perforation, gastric outlet obstruction and intractable peptic ulcer still need surgical treatment. The first laparoscopic Billroth II gastrectomy was performed in 1992. To date, laparoscopic gastrectomy has been performed by a small number of surgeons around the world. The aim of this study was to present a case of totally laparoscopic Billroth II gastrectomy and to describe an alternative technique using endoscopic stapling devices. We present a case of a 48-year-old man, complaining of severe epigastralgia, who had a 20-year history of peptic ulcer. Gastroscopy had revealed a duodenal ulcer and a deformity of the bulbus. A diagnosis of intractable peptic ulcer was made, and the patient underwent laparoscopic Billroth II gastrectomy with side-to-side intracorporeal gastrojejunostomy using endoscopic stapling devices. On postoperative day 1, he was able to walk. On postoperative day 3, he started on a clear liquid diet and was discharged on postoperative day 6. During his postoperative recovery, the patient experienced little pain and did not request narcotic analgesia. Laparoscopic gastric resection is an alternative to open procedure in well selected cases.
 ...
PMID:[Videolaparoscopy gastrectomy for complicated peptic ulcer: technique and case report]. 1075 3

Forty-five adults undergoing thoracotomy were randomized to receive placebo, tenoxicam 20 mg or tenoxicam 40 mg IV during chest wall closure. All patients received intraoperative fentanyl and intercostal blocks followed by morphine by patient-controlled analgesia. Patient numbers 13 to 45 also received thoracic epidural analgesia by continuous infusion of bupivacaine 0.125%, patient numbers 25 to 45 having fentanyl 2 microg/ml added to the epidural infusion. Efficacy parameters and adverse reactions were assessed over the first 24 hours postoperatively. On a 100 mm visual analogue scale, mean (SD) pain at rest (adjusted area under curve for hours 1 to 24) was 25.8 (12.5), 17.4 (14.8) and 16.5 (13.3) mm for groups receiving placebo, 20 mg and 40 mg tenoxicam, respectively (ANOVA: P<0.05). There were no significant differences between study groups postoperatively in pain on coughing, opioid consumption, blood gas measurements, nausea, vomiting, sedation, blood loss, haemoglobin or serum creatinine. One patient in each tenoxicam group reported epigastric pain, rated moderate. These data support the inclusion of tenoxicam 20 mg IV in the management of pain at rest for patients undergoing thoracotomy, but do not show additional benefit for a higher dose.
 ...
PMID:Tenoxicam 20 mg or 40 mg after thoracotomy: a prospective, randomized, double-blind, placebo-controlled study. 1200 22

A 58-year-old man presented with epigastric pain that was refractory to analgesia. Before this, he was well and did not have manifestations of type 1 neurofibromatosis. Endoscopy revealed a 0.5-cm polypoid antral lesion that was snared and removed in total. Histological evaluation showed a submucosal myxoid spindle-cell proliferation. The tumor was arranged in whorls with distinct concentricity. Within the myxoid stroma, occasional eosinophils were present together with a delicate capillary network. There was no cytological atypia, areas of hypercellularity, or necrosis. The lesion was strongly positive for epithelial membrane antigen and also positive for CD34. All other markers including S-100, desmin, and CD117 were negative. The overall morphological and immunophenotypic features of this lesion are in keeping with a myxoid gastric perineurioma. This lesion needs to be separated from an inflammatory fibroid polyp and a gastrointestinal stromal tumor.
 ...
PMID:Myxoid perineurioma presenting as a gastric polyp. 2022 17

The preemptive analgesic efficacy and adverse effects of preoperatively administered piroxicam-beta-cyclodextrin for post-endoscopic sinus surgery pain was determined in a prospective, double-blind, randomized, clinical study. Seventy-five American Society of Anesthesiologists status I-II patients, aged 18-65 years, were divided into three groups with similar demographic characteristics: group 1 received 20 mg piroxicam-beta-cyclodextrin, group 2 received 40 mg piroxicam-beta-cyclodextrin and group 3 received placebo orally before induction of general anesthesia. A blinded observer recorded the incidence and severity of pain at admission to the post-anesthesia care unit (PACU), at 15, 30, and 45 min in the PACU, and 1, 2, 4, 6, and 24 h postoperatively. All patients received patient-controlled morphine analgesia during the postoperative period and consumption was recorded for 24 h. During the PACU period, mean visual analogue scale values were significantly lower in groups 1 and 2 compared to group 3 (P < 0.05). During the postoperative period, morphine consumption was 3.03 +/- 2.54, 2.7 +/- 2.8, and 5.56 +/- 3.12 mg for each group, respectively (P < 0.05). As a side effect, bleeding was observed in groups 1 and 3, nausea and vomiting in all groups, and edema only in group 3. However, no significant differences were detected in any of the parameters analyzed, which also included epigastric pain, constipation/diarrhea and headache. Similar hematological test results were obtained for all groups. Preemptive administration of piroxicam-beta-cyclodextrin effectively reduced analgesic consumption, and 40 mg of the drug was more effective than 20 mg piroxicam-beta-cyclodextrin without side effects during the postoperative period.
 ...
PMID:Evaluation of piroxicam-beta-cyclodextrin as a preemptive analgesic in functional endoscopic sinus surgery. 2060 16


1 2 Next >>